ArticleBMC pharmacology & toxicology2025
Synergistic anti-malarial, cytotoxic, and antioxidant activities of trimetallic (Au-Pt-Pd) and bimetallic (Au-Pt) nanofluids: in vitro and computational insights.
Article in BMC pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Vitamin BRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global challenge of Plasmodium falciparum resistance to current therapeutics underscores the need for innovative, mechanism-driven antimalarial agents. Noble metal–based nanofluids, owing to their tunable redox and catalytic properties, offer a versatile platform for drug discovery and biointerface modulation.
objectiveThis study explores the antimalarial, antioxidant, and cytotoxic potential of bimetallic (Au–Pt) and trimetallic (Au–Pt–Pd) nanofluids through an integrated experimental–computational framework, aiming to elucidate structure–activity correlations and molecular interaction mechanisms.
methodsAu–Pt and Au–Pt–Pd nanofluids were synthesized via a green, one-pot microwave-assisted reduction method and evaluated for (i) antimalarial efficacy against P. falciparum (Pf3D7 strain), (ii) antioxidant activity using DPPH radical scavenging, and (iii) cytotoxicity in HepG2 liver cells. Complementary computational analyses—including DFT calculations, molecular docking against PfNDH2 (PDB: 5JWA), 200 ns molecular dynamics simulations, and ADMET predictions—were conducted to characterize electronic reactivity, binding stability, and pharmacokinetic profiles.
resultsExperimentally, the Au–Pt nanofluid exhibited the highest antimalarial potency (IC₅₀ = 0.93 µM) and antioxidant activity (IC₅₀ = 3.95 ± 0.05 µM), outperforming the trimetallic Au–Pt–Pd formulation (IC₅₀ = 1.04 µM and 5.54 ± 0.08 µM, respectively), with reduced cytotoxicity (IC₅₀ = 38.19 µM vs. quinine 28.11 µM). Computationally, Au–Pt–Pd nanoclusters demonstrated enhanced conformational stability through lower RMSD (0.221 nm) and persistent hydrogen bonding (average 4.12 bonds) with PfNDH2, while docking energies (–9.3 and − 8.7 kcal/mol for Au–Pt–Pd and Au–Pt, respectively) supported moderate binding affinity. DFT descriptors revealed strong electron-donating tendencies, and ADMET analysis predicted favorable intestinal absorption (> 80%), low hepatotoxicity, and non-mutagenicity for both systems.
conclusionThis synergistic in vitro–in silico investigation reveals that Au–Pt nanofluids possess potent antimalarial and antioxidant activity with minimal cytotoxicity, while Au–Pt–Pd nanofluids offer superior dynamic stability at the molecular level. Together, these findings suggest that rationally engineered noble-metal nanofluids hold significant potential as modular platforms for antimalarial drug development, meriting further in vivo and mechanistic exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.